Evolocumab
REPATHA
PCSK9 Inhibitor
NADAC/unit
$281.2448
No Shortage
Tier 1: 35.9%
PA Req: 154.7%
Evolocumab dramatically lowers LDL cholesterol by blocking the PCSK9 protein.
vs. brand REPATHA: Generic saves up to -2712% per unit
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.
